August 31, 2017Current Medical Research and Opinion
Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data
Why the study?
Do NOACs (apixaban, dabigatran, rivaroxaban) reduce bleeding risk compared to warfarin in Japanese patients with non-valvular atrial fibrillation?
Population
38,662 Japanese patients with non-valvular atrial fibrillation (NVAF) newly initiated on oral anticoagulants
Comparison
Apixaban 5/2.5 mg BID, dabigatran 150/110 mg… vs Warfarin (propensity score matched)
Design
Cohort
Follow-up
up to 1 year
Authors
Discussion
Loading...
Member takes
Implication
May support lower major bleeding with apixaban or dabigatran versus warfarin in Japanese NVAF; leaves open prospective confirmation.
Structured PICO
Do NOACs (apixaban, dabigatran, rivaroxaban) reduce bleeding risk compared to warfarin in Japanese patients with non-valvular atrial fibrillation?
P
Population
38,662 Japanese patients with non-valvular atrial fibrillation (NVAF) newly initiated on oral anticoagulants
I
Intervention
Apixaban 5/2.5 mg BID, dabigatran 150/110 mg BID, or rivaroxaban 15/10 mg QD
C
Comparator
Warfarin (propensity score matched)
O
Outcome
Risk of major bleeding at up to 1 year post-first prescriptionsafety
In a real-world Japanese cohort, apixaban, dabigatran, and low-dose rivaroxaban were associated with a significantly lower risk of major bleeding compared to warfarin in patients with non-valvular atrial fibrillation.
Cite This Study
Kohsaka et al. (2017) studied this question.